Q4 2024 Elutia Inc Earnings Call Transcript
Key Points
- Elutia Inc (ELUT) successfully launched its EluPro product, receiving FDA clearance for use in cardiac implantable electronic devices and neurostimulators.
- The company demonstrated operational excellence by completing an FDA site inspection with no deficiencies and commenced commercial production.
- Elutia Inc (ELUT) achieved significant growth in its BioEnvelope sales, with an 18% increase in the fourth quarter.
- The company secured 67 hospital and GPO approvals, surpassing its initial goal of 25, indicating strong market acceptance.
- Elutia Inc (ELUT) raised $15 million in gross proceeds through a registered direct offering, strengthening its cash position.
- SimpliDerm product sales experienced a decline in the fourth quarter, attributed to disruptions from Sientra's bankruptcy.
- Overall revenue for the quarter was down 7% compared to the same quarter of the prior year.
- The company reported a loss from operations of $8.4 million, consistent with the previous year.
- Cash usage was higher than in recent quarters due to settling outstanding lawsuits, impacting the cash balance.
- Elutia Inc (ELUT) faces ongoing litigation challenges, with 43 cases still unresolved at the end of the year.
Good afternoon, ladies and gentlemen. Welcome to the Elutia fourth quarter and full year 2024 financial results conference call. (Operator Instructions) Please be advised that today's conference call is being recorded.
I would now like to hand the conference call over to David Carey, FINN Partners. Please go ahead.
Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the quarter and full year ended, December 31, 2024. A copy of the press release is available on the company's website.
Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
